Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Company Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 08/06/2024 am IST 		5-day change 1st Jan Change
27.77 USD -2.73% Intraday chart for Genmab A/S -1.52% -12.78%
04/06 Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
03/06 Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees: 2,286

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Jan van de Winkel CEO
 Chief Executive Officer 63 01/99/01
Anthony Pagano DFI
 Director of Finance/CFO 46 01/07/01
Anthony Mancini COO
 Chief Operating Officer 53 23/20/23
Tahamtan Ahmadi CTO
 Chief Tech/Sci/R&D Officer 51 01/17/01
Marisol Peron IRO
 Public Communications Contact - 11/19/11
Christopher Cozic HRO
 Human Resources Officer 46 -
Judith Klimovsky PRN
 Corporate Officer/Principal 67 09/17/09
Martine van Vugt PRN
 Corporate Officer/Principal 71 01/01/01
Birgitte Stephensen LAW
 General Counsel 63 01/02/01

Members of the board

Members of the board TitleAgeSince
Deirdre Connelly CHM
 Chairman 63 01/17/01
Anders Gersel Pedersen BRD
 Director/Board Member 73 01/03/01
Rolf K. Hoffmann BRD
 Director/Board Member 64 01/16/01
Elizabeth O'Farrell BRD
 Director/Board Member 59 29/22/29
Pernille Erenbjerg BRD
 Director/Board Member 57 01/15/01
Paolo Augusto Paoletti BRD
 Director/Board Member 73 01/15/01
Mijke Zachariasse BRD
 Director/Board Member 51 29/19/29
Martin Schultz BRD
 Director/Board Member 49 01/22/01
Takahiro Hamatani BRD
 Director/Board Member 50 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,129,923 65,143,457 ( 98.51 %) 981,465 ( 1.484 %) 98.51 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.896 %
3,237,113 4.896 % 908 M $
GENMAB A/S
2.493 %
1,648,237 2.493 % 462 M $
Jan van de Winkel
0.9082 %
600,497 0.9082 % 168 M $
Nykredit Bank A/S (Investment Management)
0.4620 %
305,489 0.4620 % 86 M $
Amundi Asset Management SA (Investment Management)
0.3156 %
208,668 0.3156 % 59 M $
Danske Bank A/S (Investment Management)
0.2283 %
150,968 0.2283 % 42 M $
Robert W. Baird & Co., Inc. (Equity)
0.1861 %
123,067 0.1861 % 35 M $
State Street Global Advisors Ltd.
0.1685 %
111,413 0.1685 % 31 M $
Sjunde AP-fonden
0.1444 %
95,465 0.1444 % 27 M $
S.W. Mitchell Capital LLP
0.1354 %
89,501 0.1354 % 25 M $
NameEquities%Valuation
AllianceBernstein LP
2.307 %
15,254,347 2.307 % 419 M $
BlackRock Advisors LLC
0.7591 %
5,019,269 0.7591 % 138 M $
Capital Research & Management Co. (International Investors)
0.6614 %
4,373,277 0.6614 % 120 M $
Harding Loevner LP
0.4983 %
3,294,728 0.4983 % 90 M $
Wellington Management Co. LLP
0.3526 %
2,331,814 0.3526 % 64 M $
RBC CMA LLC
0.2732 %
1,806,502 0.2732 % 50 M $
Renaissance Technologies LLC
0.2055 %
1,358,600 0.2055 % 37 M $
Wells Fargo Bank NA
0.1931 %
1,276,518 0.1931 % 35 M $
First Trust Advisors LP
0.1860 %
1,229,570 0.1860 % 34 M $
U.S. Trust Company of Delaware
0.1677 %
1,109,117 0.1677 % 30 M $

Holdings

NameEquities%Valuation
GENMAB A/S
2.85%
 1,881,559 2.85% 527,754,194 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab A/S(GMAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930 DKK
Average target price
2,464 DKK
Spread / Average Target
+27.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.21B
ARGENX SE Stock argenx SE
+3.23% 22.78B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.66B
INSMED INCORPORATED Stock Insmed Incorporated
+83.45% 9.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GMAB Stock
  5. Company Genmab A/S